[go: up one dir, main page]

CO5160319A1 - Formulaciones de liberacion controlada de metamizol - Google Patents

Formulaciones de liberacion controlada de metamizol

Info

Publication number
CO5160319A1
CO5160319A1 CO99068639A CO99068639A CO5160319A1 CO 5160319 A1 CO5160319 A1 CO 5160319A1 CO 99068639 A CO99068639 A CO 99068639A CO 99068639 A CO99068639 A CO 99068639A CO 5160319 A1 CO5160319 A1 CO 5160319A1
Authority
CO
Colombia
Prior art keywords
controlled release
release formulations
metamizol
subjecting
fatty acid
Prior art date
Application number
CO99068639A
Other languages
English (en)
Inventor
Mauro Valenti
Flavio Fabiani
Original Assignee
Formenti Farmaceutici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formenti Farmaceutici Spa filed Critical Formenti Farmaceutici Spa
Publication of CO5160319A1 publication Critical patent/CO5160319A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULACIONES DE LIBERACIÓN CONTROLADA DE METAMIZOLSe obtienen formulaciones de liberación controlada sólidas, de administración por vía oral al someter el ingrediente activo y un compuesto de ácido graso a proceso de granulación por fusión y mezclado posterior del granulado obtenido con un polímero hidrofílico y excipientes convencionales.
CO99068639A 1998-11-03 1999-10-29 Formulaciones de liberacion controlada de metamizol CO5160319A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002365A IT1303693B1 (it) 1998-11-03 1998-11-03 Composizioni a rilascio controllato di metamizolo.

Publications (1)

Publication Number Publication Date
CO5160319A1 true CO5160319A1 (es) 2002-05-30

Family

ID=11380995

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99068639A CO5160319A1 (es) 1998-11-03 1999-10-29 Formulaciones de liberacion controlada de metamizol

Country Status (6)

Country Link
AR (1) AR020998A1 (es)
AU (1) AU1155000A (es)
CO (1) CO5160319A1 (es)
IT (1) IT1303693B1 (es)
PE (1) PE20001231A1 (es)
WO (1) WO2000025750A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19920415A1 (de) * 1999-05-04 2000-11-09 Hexal Ag Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
EP3265097A4 (en) * 2015-03-03 2018-11-07 Kindred Biosciences Inc. Compositions and methods for treatment and prevention of pyrexia in horses
WO2018087109A1 (de) 2016-11-08 2018-05-17 Grünenthal GmbH Multipartikuläre arzneiform mit kontrollierter freisetzung von metamizol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971743B1 (de) * 1997-04-18 2006-07-12 Fritz Stanislaus Stabilisiertes arzneimittel enthaltend cysteinylderivate

Also Published As

Publication number Publication date
PE20001231A1 (es) 2000-11-29
AU1155000A (en) 2000-05-22
WO2000025750A1 (en) 2000-05-11
AR020998A1 (es) 2002-06-05
ITMI982365A1 (it) 2000-05-03
IT1303693B1 (it) 2001-02-23

Similar Documents

Publication Publication Date Title
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DE60120710D1 (de) Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
NO20020939L (no) Oral administreringsform
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
AR070670A2 (es) Tableta de hidrobromuro de galantamina de disolucion rapida y proceso para prepararla
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
EE200100161A (et) Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
BR0308989A (pt) Formulações de claritromicina com biodisponibilidade aperfeiçoada e processo de preparação das mesmas
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
CO5170438A1 (es) Proceso para la preparacion de un comprimido de betahistina de liberacion controlada por granulacion en estado fundido y comprimido de liberacion controlada de betahistina obtenido mediante dicho proceso
CO5160319A1 (es) Formulaciones de liberacion controlada de metamizol
ECSP993186A (es) Formulaciones de liberacion controlada de metamizol
UY27596A1 (es) Formulación oral de fludara purísimo con liberación rátida del ingrediente
ECSP003358A (es) Composiciones de betahistina de liberacion controlada
WO2020086705A3 (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
CR7380A (es) Formulacion oral de fludara purisimo con liberacion rapida del ingrediente activo